SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-20-005293
Filing Date
2020-04-22
Accepted
2020-04-22 17:08:50
Documents
5
Period of Report
2020-04-22
Effectiveness Date
2020-04-22

Document Format Files

Seq Description Document Type Size
1 DEF 14A oysterpoint-2020proxyxnoti.htm DEF 14A 42579
2 notice11.jpg GRAPHIC 94736
3 notice21.jpg GRAPHIC 123631
4 notice31.jpg GRAPHIC 40119
5 notice41.jpg GRAPHIC 27110
  Complete submission text file 0001628280-20-005293.txt   437121
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39112 | Film No.: 20808523
SIC: 2836 Biological Products, (No Diagnostic Substances)